<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ELIXOPHYLLINÂ - theophylline anhydrousÂ liquidÂ </strong><br>Caraco Pharma, Inc.<br></p></div>
<h1>Rx Only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Theophylline is structurally classified as a methylxanthine. It occurs as a white, odorless, crystalline powder with a bitter taste. Anhydrous theophylline has the chemical name 1H-Purine- 2,6-dione, 3,7-dihydro-1,3 -dimethyl-, and is represented by the following structural formula:</p>
<p><img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2676f761-4fe5-40a9-a07d-ed2542847883&amp;name=elixophyllin-struct.jpg"></p>
<p>The molecular formula of anhydrous theophylline is C7H8N4O2 with a molecular weight of 180.17.Â </p>
<p>ELIXOPHYLLIN Elixir is available as a liquid intended for oral administration, containing 80 mg of theophylline anhydrous and 20% alcohol in each 15 mL (tablespoonful).</p>
<p>ELIXOPHYLLIN Elixir also contains the following inactive ingredients: anhydrous citric acid, glycerin, saccharin sodium, artificial tutti fruiti flavor #051880A, FD&amp;C red #40 and purified water. ELIXOPHYLLIN Elixir has a pH of 3.0-4.0.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Action:</h2>
<p class="First">Theophylline has two distinct actions in the airways of patients with reversible obstruction; smooth <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> (i.e., bronchodilation) and suppression of the response of the airways to stimuli (i.e., non-bronchodilator <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> effects). While the mechanisms of action of theophylline are not known with certainty, studies in animals suggest that bronchodilatation is mediated by the inhibition of two isozymes of phosphodiesterase (PDE III and, to a lesser extent, PDE IV) while non-bronchodilator <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> actions are probably mediated through one or more different molecular mechanisms, that do not involve inhibition of PDE III or antagonism of adenosine receptors. Some of the adverse effects associated with theophylline appear to be mediated by inhibition of PDE III (e.g., <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>) and adenosine receptor antagonism (e.g., alterations in cerebral blood flow).</p>
<p>Theophylline increases the force of contraction of diaphragmatic muscles. This action appears to be due to enhancement of calcium uptake through an adenosine-mediated channel.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.2"></a><a name="section-2.2"></a><p></p>
<h2>Serum Concentration-Effect Relationship:</h2>
<p class="First">Bronchodilation occurs over the serum theophylline concentration range of 5-20 mcg/mL. Clinically important improvement in symptom control has been found in most studies to require peak serum theophylline concentrations &gt;10 mcg/mL, but patients with mild disease may benefit from lower concentrations. At serum theophylline concentrations &gt;20mcg/mL, both the frequency and severity of adverse reactions increase. In general, maintaining peak serum theophylline concentrations between 10 and 15 mcg/mL will achieve most of the drugâ€™s potential therapeutic benefit while minimizing the risk of serious adverse events.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3"></a><a name="section-2.3"></a><p></p>
<h2>Pharmacokinetics:</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.1"></a><a name="section-2.3.1"></a><p></p>
<h3><span class="Bold"><span class="Underline">Overview</span></span></h3>
<p class="First">Theophylline is rapidly and completely absorbed after oral administration in solution or immediate-release solid oral dosage form. Theophylline does not undergo any appreciable pre-systemic elimination, distributes freely into fat-free tissues and is extensively metabolized in the liver.</p>
<p>The pharmacokinetics of theophylline vary widely among similar patients and cannot be predicted by age, sex, body weight or other demographic characteristics. In addition, certain concurrent illnesses and alterations in normal physiology (see Table I) and co-administration of other drugs (see Table II) can significantly alter the pharmacokinetic characteristics of theophylline. Within-subject variability in metabolism has also been reported in some studies, especially in acutely ill patients. It is, therefore, recommended that serum theophylline concentrations be measured frequently in acutely ill patients (e.g., at 24-hour intervals) and periodically in patients receiving long-term therapy, e.g., at 6-12 month intervals. More frequent measurements should be made in the presence of any condition that may significantly alter theophylline clearance (see <a href="#Section_6.3">PRECAUTIONS, Laboratory tests</a>).</p>
<a name="table1"></a><table frame="void">
<caption><span>Table I. Mean and range of total body clearance and half-life of theophylline related to age and altered physiological states.Â¶</span></caption>
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="top"><span class="Bold">Population characteristics</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Total body clearance*<br> mean (range)â€ â€ <br>(mL/kg/min)</span></td>
<td class="Botrule" align="center" valign="top"><span class="Bold">Half-life<br> mean (range)â€ â€ <br> (hr)</span></td>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top">Â¶For various North American patient populations from literature reports. Different rates of elimination and consequent dosage requirements have been observed among other peoples.</td></tr>
<tr><td align="left" colspan="3" valign="top">*Clearance represents the volume of blood completely cleared of theophylline by the liver in one minute. Values listed were generally determined at serum theophylline concentrations &lt;20 mcg/mL; clearance may decrease and half-life may increase at higher serum concentrations due to non-linear pharmacokinetics.</td></tr>
<tr><td align="left" colspan="3" valign="top">â€ â€ Reported range or estimated range (mean Â± 2 SD) where actual range not reported.</td></tr>
<tr><td align="left" colspan="3" valign="top">â€ NR = not reported or not reported in a comparable format.</td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top">**Median</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top"><span class="Bold"><span class="Underline">Age</span></span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline">Premature neonates</span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">postnatal age 3-15 days</td>
<td align="center" valign="top">0.29 (0.09-0.49)</td>
<td align="center" valign="top">30 (17-43)</td>
</tr>
<tr>
<td align="left" valign="top">postnatal age 25-57 days</td>
<td align="center" valign="top">0.64 (0.04-1.2)</td>
<td align="center" valign="top">20 (9.4-30.6)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline">Term infants</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">postnatal age 1-2 days</td>
<td align="center" valign="top">NRâ€ </td>
<td align="center" valign="top">25.7 (25-26.5)</td>
</tr>
<tr>
<td align="left" valign="top">postnatal age 3-30 weeks</td>
<td align="center" valign="top">NRâ€ </td>
<td align="center" valign="top">11 (6-29)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline">Children</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">1-4 years</td>
<td align="center" valign="top">1.7 (0.5-2.9)</td>
<td align="center" valign="top">3.4 (1.2-5.6)</td>
</tr>
<tr>
<td align="left" valign="top">4-12 years</td>
<td align="center" valign="top">1.6 (0.8-2.4)</td>
<td align="center" valign="top">NRâ€ </td>
</tr>
<tr>
<td align="left" valign="top">13-15 years</td>
<td align="center" valign="top">0.9 (0.48-1.3)</td>
<td align="center" valign="top">NRâ€ </td>
</tr>
<tr>
<td align="left" valign="top">16-17 years</td>
<td align="center" valign="top">1.4 (0.2-2.6)</td>
<td align="center" valign="top">3.7 (1.5-5.9)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline">Adults (16-60 years)</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">otherwise healthy</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">non-smoking <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatics</span></td>
<td align="center" valign="top">0.65 (0.27-1.03)</td>
<td align="center" valign="top">8.7 (6.1-12.8)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline"> Elderly (&gt;60 years)</span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">non-smokers with normal cardiac, liver, and renal function</td>
<td align="center" valign="top">0.41 (0.21-0.61)</td>
<td align="center" valign="top">9.8 (1.6-18)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Bold"><span class="Underline">Concurrent illness or altered physiological state</span></span></td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="261600" conceptname="Acute pulmonary edema">Acute pulmonary edema</span></td>
<td align="center" valign="top">0.33** (0.07-2.45)</td>
<td align="center" valign="top">19** (3.1-82)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>-&gt;60 years, stable<br> non-smoker &gt;1 year</td>
<td align="center" valign="top">0.54 (0.44-0.64)</td>
<td align="center" valign="top">11 (9.4-12.6)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> with <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span></td>
<td align="center" valign="top">0.48 (0.08-0.88)</td>
<td align="center" valign="top">NRâ€ </td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">Cystic fibrosis</span> (14-28 years)</td>
<td align="center" valign="top">1.25 (0.31-2.2)</td>
<td align="center" valign="top">6.0 (1.8-10.2)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> associated with acute viral respiratory<br> illness (children 9-15 years)</td>
<td align="center" valign="top">NRâ€ </td>
<td align="center" valign="top">7.0 (1.0-13)</td>
</tr>
<tr>
<td align="left" valign="top">Liver disease -Â  cirrhosis</td>
<td align="center" valign="top">0.31** (0.1-0.7)</td>
<td align="center" valign="top">32** (10-56)</td>
</tr>
<tr>
<td align="left" valign="top">acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span></td>
<td align="center" valign="top">0.35 (0.25-0.45)</td>
<td align="center" valign="top">19.2 (16.6-21.8)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span></td>
<td align="center" valign="top">0.65 (0.25-1.45)</td>
<td align="center" valign="top">14.4 (5.7-31.8)</td>
</tr>
<tr>
<td align="left" valign="top">Pregnancy -Â 1st trimester</td>
<td align="center" valign="top">NRâ€ </td>
<td align="center" valign="top">8.5 (3.1-13.9)</td>
</tr>
<tr>
<td align="left" valign="top">2nd trimester</td>
<td align="center" valign="top">NRâ€ </td>
<td align="center" valign="top">8.8 (3.8-13.8)</td>
</tr>
<tr>
<td align="left" valign="top">3rd trimester</td>
<td align="center" valign="top">NRâ€ </td>
<td align="center" valign="top">13.0 (8.4-17.6)</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span> with multi-organ failure</td>
<td align="center" valign="top">0.47 (0.19-1.9)</td>
<td align="center" valign="top">18.8 (6.3-24.1)</td>
</tr>
<tr>
<td align="left" valign="top">Thyroid disease - hypothyroid</td>
<td align="center" valign="top">0.38 (0.13-0.57)</td>
<td align="center" valign="top">11.6 (8.2-25)</td>
</tr>
<tr class="Last">
<td align="left" valign="top">hyperthyroid</td>
<td align="center" valign="top">0.8 (0.68-0.97)</td>
<td align="center" valign="top">4.5 (3.7-5.6)</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Underline">Note:</span></span><span class="Bold"></span>In addition to the factors listed above, theophylline clearance is increased and half-life decreased by low carbohydrate/high protein diets, parenteral nutrition, and daily consumption of charcoal-broiled beef. A high carbohydrate/low protein diet can decrease the clearance and prolong the half-life of theophylline.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.2"></a><a name="section-2.3.2"></a><p></p>
<h3><span class="Bold"><span class="Underline">Absorption</span></span></h3>
<p class="First">Theophylline is rapidly and completely absorbed after oral administration in solution or immediate-release solid oral dosage form. After a single dose of 5 mg/kg in adults, a mean peak serum concentration of about 10 mcg/mL (range 5-15 mcg/mL) can be expected 1-2 hr after the dose. Co-administration of theophylline with food or antacids does not cause clinically significant changes in the absorption of theophylline from immediate-release dosage forms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.3"></a><a name="section-2.3.3"></a><p></p>
<h3><span class="Bold"><span class="Underline">Distribution</span></span></h3>
<p class="First">Once theophylline enters the systemic circulation, about 40% is bound to plasma protein, primarily albumin. Unbound theophylline distributes throughout body water, but distributes poorly into body fat. The apparent volume of distribution of theophylline is approximately 0.45 L/kg (range 0.3-0.7 L/kg) based on ideal body weight. Theophylline passes freely across the placenta, into breast milk and into the cerebrospinal fluid (CSF). Saliva theophylline concentrations approximate unbound serum concentrations, but are not reliable for routine or therapeutic monitoring unless special techniques are used. An increase in the volume of distribution of theophylline, primarily due to reduction in plasma protein binding, occurs in premature neonates, patients with <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span>, uncorrected <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidemia</span>, the elderly and in women during the third trimester of pregnancy. In such cases, the patient may show signs of toxicity at total (bound +unbound) serum concentrations of theophylline in the therapeutic range (10-20 mcg/mL) due to elevated concentrations of the pharmacologically active unbound drug. Similarly, a patient with decreased theophylline binding may have a subtherapeutic total drug concentration while the pharmacologically active unbound concentration is in the therapeutic range. If only total serum theophylline concentration is measured, this may lead to an unnecessary and potentially dangerous dose increase. In patients with reduced protein binding, measurement of unbound serum theophylline concentration provides a more reliable means of dosage adjustment than measurement of total serum theophylline concentration. Generally, concentrations of unbound theophylline should be maintained in the range of 6-12 mcg/mL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.4"></a><a name="section-2.3.4"></a><p></p>
<h3><span class="Bold"><span class="Underline">Metabolism</span></span></h3>
<p class="First">Following oral dosing, theophylline does not undergo any measurable first-pass elimination. In adults and children beyond one year of age, approximately 90% of the dose is metabolized in the liver. Biotransformation takes place through demethylation to 1-methylxanthine and 3-methylxanthine and hydroxylation to 1,3-dimethyluric acid. 1-methylxanthine is further hydroxylated, by xanthine oxidase, to 1-methyluric acid. About 6% of a theophylline dose is N-methylated to caffeine. Theophylline demethylation to 3-methylxanthine is catalyzed by cytochrome P-450 1A2, while cytochromes P-450 2E1 and P-450 3A3 catalyze the hydroxylation to 1,3-dimethyluric acid. Demethylation to 1-methylxanthine appears to be catalyzed either by cytochrome P-450 1A2 or a closely related cytochrome. In neonates, the N-demethylation pathway is absent while the function of the hydroxylation pathway is markedly deficient. The activity of these pathways slowly increases to maximal levels by one year of age.</p>
<p>Caffeine and 3-methylxanthine are the only theophylline metabolites with pharmacologic activity. 3-methylxanthine has approximately one tenth the pharmacologic activity of theophylline and serum concentrations in adults with normal renal function are &lt;1 mcg/mL. In patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, 3-methylxanthine may accumulate to concentrations that approximate the unmetabolized theophylline concentration. Caffeine concentrations are usually undetectable in adults regardless of renal function. In neonates, caffeine may accumulate to concentrations that approximate the unmetabolized theophylline concentration and thus, exert a pharmacologic effect.</p>
<p>Both the N-demethylation and hydroxylation pathways of theophylline biotransformation are capacity-limited. Due to the wide intersubject variability of the rate of theophylline metabolism, non-linearity of elimination may begin in some patients at serum theophylline concentrations &lt;10 mcg/mL. Since this non-linearity results in more than proportional changes in serum theophylline concentrations with changes in dose, it is advisable to make increases or decreases in dose in small increments in order to achieve desired changes in serum theophylline concentrations (see <a href="#table6">DOSAGE AND ADMINISTRATION, Table VI)</a>. Accurate prediction of dose-dependency of theophylline metabolism in patients a <span class="Italics">priori </span>is not possible, but patients with very high initial clearance rates (i.e., low steady state serum theophylline concentrations at above average doses) have the greatest likelihood of experiencing large changes in serum theophylline concentration in response to dosage changes.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.5"></a><a name="section-2.3.5"></a><p></p>
<h3><span class="Bold"><span class="Underline">Excretion</span></span></h3>
<p class="First">In neonates, approximately 50% of the theophylline dose is excreted unchanged in the urine. Beyond the first three months of life, approximately 10% of the theophylline dose is excreted unchanged in the urine. The remainder is excreted in the urine mainly as 1,3-dimethyluric acid (35-40%), 1-methyluric acid (20-25%) and 3-methylxanthine (15-20%). Since little theophylline is excreted unchanged in the urine and since active metabolites of theophylline (i.e., caffeine, 3-methylxanthine) do not accumulate to clinically significant levels even in the face of end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, no dosage adjustment for <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> is necessary in adults and children &gt;3 months of age. In contrast, the large fraction of the theophylline dose excreted in the urine as unchanged theophylline and caffeine in neonates requires careful attention to dose reduction and frequent monitoring of serum theophylline concentrations in neonates with reduced renal function (See <a href="#Section_5">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.6"></a><a name="section-2.3.6"></a><p></p>
<h3><span class="Bold"><span class="Underline">Serum Concentrations at Steady State</span></span></h3>
<p class="First">After multiple doses of theophylline, steady state is reached in 30-65 hours (average 40 hours) in adults. At steady state, on a dosage regimen with 6-hour intervals, the expected mean trough concentration is approximately 60% of the mean peak concentration, assuming a mean theophylline half-life of 8 hours. The difference between peak and trough concentrations is larger in patients with more rapid theophylline clearance. In patients with high theophylline clearance and half-lives of about 4-5 hours, such as children age 1 to 9 years, the trough serum theophylline concentration may be only 30% of peak with a 6-hour dosing interval. In these patients a slow release formulation would allow a longer dosing interval (8-12 hours) with a smaller peak/trough difference.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.7"></a><a name="section-2.3.7"></a><p></p>
<h3><span class="Bold"><span class="Underline">Special Populations (See Table I for mean clearance and half-life values)</span></span></h3>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.7.1"></a><a name="section-2.3.7.1"></a><p></p>
<h4><span class="Underline">Geriatric</span></h4>
<p class="First">The clearance of theophylline is decreased by an average of 30% in healthy elderly adults (&gt; 60 yrs) compared to healthy young adults. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in elderly patients (see <a href="#Section_5">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.7.2"></a><a name="section-2.3.7.2"></a><p></p>
<h4><span class="Underline">Pediatrics</span></h4>
<p class="First">The clearance of theophylline is very low in neonates (see <a href="#Section_5">WARNINGS</a>). Theophylline clearance reaches maximal values by one year of age, remains relatively constant until about 9 years of age and then slowly decreases by approximately 50% to adult values at about age 16. Renal excretion of unchanged theophylline in neonates amounts to about 50% of the dose, compared to about 10% in children older than three months and in adults. Careful attention to dosage selection and monitoring of serum theophylline concentrations are required in pediatric patients (see <a href="#Section_5">WARNINGS</a> and <a href="#Section_10">DOSAGE AND ADMINISTRATION</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.7.3"></a><a name="section-2.3.7.3"></a><p></p>
<h4><span class="Underline">Gender</span></h4>
<p class="First">Gender differences in theophylline clearance are relatively small and unlikely to be of clinical significance. Significant reduction in theophylline clearance, however, has been reported in women on the 20th day of the menstrual cycle and during the third trimester of pregnancy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.7.4"></a><a name="section-2.3.7.4"></a><p></p>
<h4><span class="Underline">Race</span></h4>
<p class="First">Pharmacokinetic differences in theophylline clearance due to race have not been studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.7.5"></a><a name="section-2.3.7.5"></a><p></p>
<h4><span class="Underline"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Insufficiency</span></span></h4>
<p class="First">Only a small fraction, e.g., about 10%, of the administered theophylline dose is excreted unchanged in the urine of children greater than three months of age and adults. Since little theophylline is excreted unchanged in the urine and since active metabolites of theophylline (i.e., caffeine, 3-methylxanthine) do not accumulate to clinically significant levels even in the face of end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, no dosage adjustment for <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> is necessary in adults and children &gt;3 months of age. In contrast, approximately 50% of the administered theophylline dose is excreted unchanged in the urine in neonates. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in neonates with decreased renal function (see <a href="#Section_5">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.7.6"></a><a name="section-2.3.7.6"></a><p></p>
<h4><span class="Underline"><span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">Hepatic Insufficiency</span></span></h4>
<p class="First">Theophylline clearance is decreased by 50% or more in patients with <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic insufficiency</span> (e.g., cirrhosis, acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>). Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients with reduced hepatic function (see <a href="#Section_5">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.7.7"></a><a name="section-2.3.7.7"></a><p></p>
<h4><span class="Underline"><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span> (CHF)</span></h4>
<p class="First">Theophylline clearance is decreased by 50% or more in patients with CHF. The extent of reduction in theophylline clearance in patients with CHF appears to be directly correlated to the severity of the cardiac disease. Since theophylline clearance is independent of liver blood flow, the reduction in clearance appears to be due to impaired hepatocyte function rather than reduced perfusion. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients with CHF (see <a href="#Section_5">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.7.8"></a><a name="section-2.3.7.8"></a><p></p>
<h4><span class="Underline">Smokers</span></h4>
<p class="First">Tobacco and marijuana smoking appears to increase the clearance of theophylline by induction of metabolic pathways. Theophylline clearance has been shown to increase by approximately 50% in young adult tobacco smokers and by approximately 80% in elderly tobacco smokers compared to non-smoking subjects. Passive smoke exposure has also been shown to increase theophylline clearance by up to 50%. Abstinence from tobacco smoking for one week causes a reduction of approximately 40% in theophylline clearance. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients who stop smoking (see <a href="#Section_5">WARNINGS</a>). Use of nicotine gum has been shown to have no effect on theophylline clearance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.7.9"></a><a name="section-2.3.7.9"></a><p></p>
<h4><span class="Underline"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></span></h4>
<p class="First"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>, regardless of its underlying cause, can decrease the clearance of theophylline. The magnitude and duration of the <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> appear to be directly correlated to the degree of decrease of theophylline clearance. Precise data are lacking, but a temperature of 39<span class="Sup">o</span>C (102<span class="Sup">o</span>F) for at least 24 hours is probably required to produce a clinically significant increase in serum theophylline concentrations. Children with rapid rates of theophylline clearance (i.e., those who require a dose that is substantially larger than average [e.g., &gt;22 mg/kg/day] to achieve a therapeutic peak serum theophylline concentration when afebrile) may be at greater risk of toxic effects from decreased clearance during sustained <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients with sustained <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (see <a href="#Section_5">WARNINGS</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.3.7.10"></a><a name="section-2.3.7.10"></a><p></p>
<h4><span class="Underline">Miscellaneous</span></h4>
<p class="First">Other factors associated with decreased theophylline clearance include the third trimester of pregnancy, <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> with <span class="product-label-link" type="condition" conceptid="4212484" conceptname="Multiple organ failure">multiple organ failure</span>, and <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>. Careful attention to dose reduction and frequent monitoring of serum theophylline concentrations are required in patients with any of these conditions (see <a href="#Section_5">WARNINGS</a>). Other factors associated with increased theophylline clearance include <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span> and <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span>.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_2.3.7.11"></a><a name="section-2.3.7.11"></a><p></p>
<h4><span class="Bold">Clinical studies:</span></h4>
<p class="First">In patients with chronic <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, including patients with severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> requiring inhaled corticosteroids or alternate-day oral corticosteroids, many clinical studies have shown that theophylline decreases the frequency and severity of symptoms, including nocturnal exacerbations, and decreases the â€œas neededâ€? use of inhaled beta-2 agonists. Theophylline has also been shown to reduce the need for short courses of daily oral prednisone to relieve exacerbations of airway obstruction that are unresponsive to bronchodilators in <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthmatics</span>.</p>
<p>In patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>), clinical studies have shown that theophylline decreases <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, air trapping, the work of breathing, and improves contractility of diaphragmatic muscles with little or no improvement in pulmonary function measurements.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and other chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung diseases</span>, e.g., <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span> and <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">ELIXOPHYLLIN Elixir is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to theophylline or other components in the product.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>Concurrent Illness:</h2>
<p class="First">Theophylline should be used with extreme caution in patients with the following clinical conditions due to the increased risk of exacerbation of the concurrent condition:</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Active <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer disease</span></p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> disorders</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac arrhythmias</span> (not including <span class="product-label-link" type="condition" conceptid="4228448" conceptname="Bradyarrhythmia">bradyarrhythmias</span>)</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>Conditions That Reduce Theophylline Clearance:</h2>
<p class="First">There are several readily identifiable causes of reduced theophylline clearance. <span class="Bold"><span class="Underline">If the total daily dose is not appropriately reduced in the presence of these risk factors, severe and potentially fatal theophylline toxicity can occur. </span></span>Careful consideration must be given to the benefits and risks of theophylline use and the need for more intensive monitoring of serum theophylline concentrations in patients with the following risk factors:</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â  <span class="Bold"><span class="Underline">Age</span></span></p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â  Neonates (term and premature)</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â  Children &lt;1 year</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â  Elderly (&gt;60 years)</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â  <span class="Bold"><span class="Underline"> Concurrent Diseases</span></span></p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="261600" conceptname="Acute pulmonary edema">Acute pulmonary edema</span></p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span></p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">Cor pulmonale</span></p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span>; â‰¥102<span class="Sup">o</span>F for 24 hours or more; or lesser temperature elevations for longer periods</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">Hypothyroidism</span></p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â  Liver disease; cirrhosis, acute <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span></p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â  Reduced renal function in infants &lt;3 months of age</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â  <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Sepsis</span> with multi-organ failure</p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â  ShockÂ </p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â  <span class="Bold"><span class="Underline"> <span class="product-label-link" type="condition" conceptid="4310250" conceptname="Ex-smoker">Cessation of Smoking</span></span></span><span class="Bold"></span></p>
<p>Â Â Â Â Â Â Â Â Â Â Â Â  <span class="Bold"><span class="Underline">Drug Interactions</span></span> Adding a drug that inhibits theophylline metabolism (e.g., cimetidine, erythromycin, tacrine) or</p>
<p> Â Â Â Â Â Â Â Â Â Â Â Â  stopping a concurrently administered drug that enhances theophylline metabolism (e.g., carbamazepine, rifampin).</p>
<p> Â Â Â Â Â Â Â Â Â Â Â Â  (see <a href="#table2">PRECAUTIONS , Drug Interactions, Table II</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>When Signs or Symptoms of Theophylline Toxicity Are Present:</h2>
<p class="First"><span class="Bold"><span class="Underline">Whenever a patient receiving theophylline develops <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, particularly repetitive <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or other signs or symptoms consistent with theophylline toxicity (even if another cause may be suspected), additional doses of theophylline should be withheld and a serum theophylline concentration measured immediately. </span></span>Patients should be instructed not to continue any dosage that causes adverse effects and to withhold subsequent doses until the symptoms have resolved, at which time the clinician may instruct the patient to resume the drug at a lower dosage (see <a href="#table6">DOSAGE AND ADMINISTRATION, Dosing Guidelines, Table VI</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>Dosage Increases:</h2>
<p class="First">Increases in the dose of theophylline should not be made in response to an acute exacerbation of symptoms of chronic <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> since theophylline provides little added benefit to inhaled beta<span class="Sub">2</span>-selective agonists and systemically administered corticosteroids in this circumstance and increases the risk of adverse effects. A <span class="Underline">peak</span> steady state serum theophylline concentration should be measured before increasing the dose in response to persistent chronic symptoms to ascertain whether an increase in dose is safe. Before increasing the theophylline dose on the basis of a low serum concentration, the clinician should consider whether the blood sample was obtained at an appropriate time in relationship to the dose and whether the patient has adhered to the prescribed regimen (see <a href="#Section_6.3">PRECAUTIONS, Laboratory Tests</a>).</p>
<p>As the rate of theophylline clearance may be dose-dependent (i.e., steady-state serum concentrations may increase disproportionately to the increase in dose), an increase in dose based upon a sub-therapeutic serum concentration measurement should be conservative. In general, limiting dose increases to about 25% of the previous total daily dose will reduce the risk of unintended excessive increases in serum theophylline concentration (see <a href="#table6">DOSAGE AND ADMINISTRATION, Table VI</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>General </h2>
<p class="First">Careful consideration of the various interacting drugs and physiologic conditions that can alter theophylline clearance and require dosage adjustment should occur prior to initiation of theophylline therapy, prior to increases in theophylline dose, and during follow up (see <a href="#Section_5">WARNINGS</a>). The dose of theophylline selected for initiation of therapy should be low and, <span class="Bold">if tolerated, </span>increased slowly over a period of a week or longer with the final dose guided by monitoring serum theophylline concentrations and the patientâ€™s clinical response (see <a href="#table5">DOSAGE AND ADMINISTRATION, Table V</a>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.12"></a><a name="section-6.2"></a><p></p>
<h2>Monitoring Serum Theophylline Concentrations:</h2>
<p class="First">Serum theophylline concentration measurements are readily available and should be used to determine whether the dosage is appropriate. Specifically, the serum theophylline concentration should be measured as follows:</p>
<ol class="Arabic">
<li>When initiating therapy to guide final dosage adjustment after titration.</li>
<li>Before making a dose increase to determine whether the serum concentration is sub-therapeutic in a patient who continues to be symptomatic.</li>
<li>Whenever signs or symptoms of theophylline toxicity are present.</li>
<li>Whenever there is a new illness, worsening of a chronic illness or a change in the patientâ€™s treatment regimen that may alter theophylline clearance (e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> &gt;102<span class="Sup">o</span>F sustained for â‰¥24 hours, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, or drugs listed in Table II are added or discontinued).
                  </li>
</ol>
<p>To guide a dose increase, the blood sample should be obtained at the time of the expected peak serum theophylline concentration; 1-2 hours after a dose at steady-state. For most patients, steady-state will be reached after 3 days of dosing when no doses have been missed, no extra doses have been added, and none of the doses have been taken at unequal intervals. A trough concentration (i.e., at the end of the dosing interval) provides no additional useful information and may lead to an inappropriate dose increase since the peak serum theophylline concentration can be two or more times greater than the trough concentration with an immediate-release formulation. If the serum sample is drawn more than two hours after the dose, the results must be interpreted with caution since the concentration may not be reflective of the peak concentration. In contrast, when signs or symptoms of theophylline toxicity are present, the serum sample should be obtained as soon as possible, analyzed immediately, and the result reported to the clinician without delay. In patients in whom decreased serum protein binding is suspected (e.g., cirrhosis, women during the third trimester of pregnancy), the concentration of unbound theophylline should be measured and the dosage adjusted to achieve an unbound concentration of 6-12 mcg/mL.</p>
<p>Saliva concentrations of theophylline cannot be used reliably to adjust dosage without special techniques.</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="Section_6.3"></a><a name="section-6.3"></a><p></p>
<h2>Effects on Laboratory Tests</h2>
<p class="First">As a result of its pharmacological effects, theophylline at serum concentrations within the 10-20 mcg/mL range modestly increases plasma glucose (from a mean of 88 mg% to 98 mg%), uric acid (from a mean of 4 mg/dl to 6 mg/dl), free fatty acids (from a mean of 451 Î¼eq/l to 800 Î¼eq/l), total <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span> (from a mean of 140 vs 160 mg/dl), HDL (from a mean of 36 to 50 mg/dl), HDL/LDL ratio (from a mean of 0.5 to 0.7), and urinary free cortisol excretion (from a mean of 44 to 63 mcg/24 hr). Theophylline at serum concentrations within the 10-20 mcg/mL range may also transiently decrease serum concentrations of triiodothyronine (144 before, 131 after one week and 142 ng/dl after 4 weeks of theophylline). The clinical importance of these changes should be weighed against the potential therapeutic benefit of theophylline in individual patients.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_6.2"></a><a name="section-6.4"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">The patient (or parent/care giver) should be instructed to seek medical advice whenever <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, persistent <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> or rapid heart beat occurs during treatment with theophylline, even if another cause is suspected. The patient should be instructed to contact their clinician if they develop a new illness, especially if accompanied by a persistent <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, if they experience worsening of a chronic illness, if they start or stop smoking cigarettes or marijuana, or if another clinician adds a new medication or discontinues a previously prescribed medication. Patients should be instructed to inform all clinicians involved in their care that they are taking theophylline, especially when a medication is being added or deleted from their treatment. Patients should be instructed to not alter the dose, timing of the dose, or frequency of administration without first consulting their clinician. If a dose is missed, the patient should be instructed to take the next dose at the usually scheduled time and to not attempt to make up for the missed dose.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_6.4"></a><a name="section-6.5"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Theophylline interacts with a wide variety of drugs. The interaction may be pharmacodynamic, i.e., alterations in the therapeutic response to theophylline or another drug or occurrence of adverse effects without a change in serum theophylline concentration. More frequently, however, the interaction is pharmacokinetic, i.e., the rate of theophylline clearance is altered by another drug resulting in increased or decreased serum theophylline concentrations. Theophylline only rarely alters the pharmacokinetics of other drugs.</p>
<p>The drugs listed in Table II have the potential to produce clinically significant pharmacodynamic or <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interactions</span> with theophylline. The information in the â€œEffectâ€? column of Table II assumes that the interacting drug is being added to a steady-state theophylline regimen. If theophylline is being initiated in a patient who is already taking a drug that inhibits theophylline clearance (e.g., cimetidine, erythromycin), the dose of theophylline required to achieve a therapeutic serum theophylline concentration will be smaller. Conversely, if theophylline is being initiated in a patient who is already taking a drug that enhances theophylline clearance (e.g., rifampin), the dose of theophylline required to achieve a therapeutic serum theophylline concentration will be larger. Discontinuation of a concomitant drug that increases theophylline clearance will result in accumulation of theophylline to potentially toxic levels, unless the theophylline dose is appropriately reduced. Discontinuation of a concomitant drug that inhibits theophylline clearance will result in decreased serum theophylline concentrations, unless the theophylline dose is appropriately increased.Â Â  </p>
<p>The drugs listed in Table III have either been documented not to interact with theophylline or do not produce a clinically significant interaction (i.e., &lt;15% change in theophylline clearance). </p>
<p>The listing of drugs in Table II and III are current as of February 9, 1995. New interactions are continuously being reported for theophylline, especially with new chemical entities. <span class="Bold"><span class="Underline">The clinician should not assume that a drug does not interact with theophylline if it is not listed in Table II.</span></span> Before addition of a newly available drug in a patient receiving theophylline, the package insert of the new drug and/or the medical literature should be consulted to determine if an interaction between the new drug and theophylline has been reported.</p>
<a name="table2"></a><table frame="void">
<caption><span>Table II. Clinically significant drug interactions with theophylline*.</span></caption>
<thead><tr class="First Last">
<td align="left" colspan="2" valign="top"><span class="Bold">Drug</span></td>
<td align="left" valign="top"><span class="Bold">Type of Interaction</span></td>
<td align="left" valign="top"><span class="Bold">Effect**</span></td>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="4" valign="top"><span class="Bold">
                          *Refer to <a href="#Section_6.4">PRECAUTIONS, Drug Interactions</a> for further information regarding table.</span></td></tr>
<tr class="Last"><td align="left" colspan="4" valign="top"><span class="Bold">**Average effect on steady state theophylline concentration or other clinical effect for pharmacologic interactions. Individual patients may experience larger changes in serum theophylline concentration than the value listed.</span></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left" colspan="2" valign="top">Adenosine</td>
<td align="left" valign="top">Theophylline blocks adenosine receptors.</td>
<td align="left" valign="top">Higher doses of adenosine may be required to achieve desired effect.</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Alcohol</td>
<td align="left" valign="top">A single large dose of alcohol (3 ml/kg of whiskey) decreases theophylline clearance for up to 24 hours.</td>
<td align="left" valign="top">30% increase</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Allopurinol</td>
<td align="left" valign="top">
                        Decreases theophylline clearance at allopurinol doses <span class="Underline">&gt;</span>600 mg/day.
                      </td>
<td align="left" valign="top">25% increase</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Amino glutethimide</td>
<td align="left" valign="top">Increases theophylline clearance by induction of microsomal enzyme activity.</td>
<td align="left" valign="top">25% decrease</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Carbamazepine</td>
<td align="left" valign="top">Similar to aminoglutethimide.</td>
<td align="left" valign="top">30% decrease</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Cimetidine</td>
<td align="left" valign="top">Decreases theophylline clearance by inhibiting cytochrome P450 1A2.</td>
<td align="left" valign="top">70% increase</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Ciprofloxacin</td>
<td align="left" valign="top">Similar to cimetidine.</td>
<td align="left" valign="top">40% increase</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Clarithromycin</td>
<td align="left" valign="top">Similar to erythromycin.</td>
<td align="left" valign="top">25% increase</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Diazepam</td>
<td align="left" valign="top">Benzodiazepines increase CNS concentrations of adenosine, a potent CNS depressant, while theophylline blocks adenosine receptors.</td>
<td align="left" valign="top">Larger diazepam doses may be required to produce desired level of sedation. Discontinuation of theophylline without reduction of diazepam dose may result in <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Disulfiram</td>
<td align="left" valign="top">Decreases theophylline clearance by inhibiting hydroxylation and demethylation.</td>
<td align="left" valign="top">50% increase</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Enoxacin</td>
<td align="left" valign="top">Similar to cimetidine.</td>
<td align="left" valign="top">300% increase</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Ephedrine</td>
<td align="left" valign="top">Synergistic CNS effects</td>
<td align="left" valign="top">Increased frequency of <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Erythromycin</td>
<td align="left" valign="top">Erythromycin metabolite decreases theophylline clearance by inhibiting cytochrome P450 3A3.</td>
<td align="left" valign="top">35% increase. Erythromycin steady-state serum concentrations decrease by a similar amount. </td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Estrogen</td>
<td align="left" valign="top">Estrogen containing oral contraceptives decrease theophylline clearance in a dose- dependent fashion. The effect of progesterone on theophylline clearance is unknown.</td>
<td align="left" valign="top">30% increase</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Flurazepam</td>
<td align="left" valign="top">Similar to diazepam.</td>
<td align="left" valign="top">Similar to diazepam.</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Fluvoxamine</td>
<td align="left" valign="top">Similar to cimetidine</td>
<td align="left" valign="top">Similar to cimetidine</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Halothane</td>
<td align="left" valign="top">Halothane sensitizes the myocardium to catecholamines, theophylline increases release of endogenous catecholamines.</td>
<td align="left" valign="top">Increased risk of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>.</td>
</tr>
<tr>
<td align="left" colspan="2" valign="top">Interferon, human recombinant alpha-A</td>
<td align="left" valign="top">Decreases theophylline clearance.</td>
<td align="left" valign="top">100% increase</td>
</tr>
<tr>
<td align="left" valign="top">Isoproterenol (IV)</td>
<td align="left" colspan="2" valign="top">Increases theophylline clearance.</td>
<td align="left" valign="top">20% decrease</td>
</tr>
<tr>
<td align="left" valign="top">Ketamine</td>
<td align="left" colspan="2" valign="top">Pharmacologic</td>
<td align="left" valign="top">May lower theophylline <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold.</td>
</tr>
<tr>
<td align="left" valign="top">Lithium</td>
<td align="left" colspan="2" valign="top">Theophylline increases renal lithium clearance.</td>
<td align="left" valign="top">Lithium dose required to achieve a therapeutic serum concentration increased an average of 60%.</td>
</tr>
<tr>
<td align="left" valign="top">Lorazepam</td>
<td align="left" colspan="2" valign="top">Similar to diazepam.</td>
<td align="left" valign="top">Similar to diazepam.</td>
</tr>
<tr>
<td align="left" valign="top">Methotrexate (MTX)</td>
<td align="left" colspan="2" valign="top">Decreases theophylline clearance.</td>
<td align="left" valign="top">20% increase after low dose MTX, higher dose MTX may have a greater effect.</td>
</tr>
<tr>
<td align="left" valign="top">Mexiletine</td>
<td align="left" colspan="2" valign="top">Similar to disulfiram.</td>
<td align="left" valign="top">80% increase</td>
</tr>
<tr>
<td align="left" valign="top">Midazolam</td>
<td align="left" colspan="2" valign="top">Similar to diazepam.</td>
<td align="left" valign="top">Similar to diazepam.</td>
</tr>
<tr>
<td align="left" valign="top">Moricizine</td>
<td align="left" colspan="2" valign="top">Increases theophylline clearance.</td>
<td align="left" valign="top">25% decrease</td>
</tr>
<tr>
<td align="left" valign="top">Pancuronium</td>
<td align="left" colspan="2" valign="top">Theophylline may antagonize non-depolarizing neuromuscular blocking effects; possibly due to phosphodiesterase inhibition.</td>
<td align="left" valign="top">Larger dose of pancuronium may be required to achieve <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span>.</td>
</tr>
<tr>
<td align="left" valign="top">Pentoxifylline</td>
<td align="left" colspan="2" valign="top">Decreases theophylline clearance.</td>
<td align="left" valign="top">30% increase</td>
</tr>
<tr>
<td align="left" valign="top">Phenobarbital (PB)</td>
<td align="left" colspan="2" valign="top">Similar to aminoglutethimide.</td>
<td align="left" valign="top">25% decrease after two weeks of concurrent PB.</td>
</tr>
<tr>
<td align="left" valign="top">Phenytoin</td>
<td align="left" colspan="2" valign="top">Phenytoin increases theophylline clearance by increasing microsomal enzyme activity. Theophylline decreases phenytoin absorption.</td>
<td align="left" valign="top">Serum theophylline and phenytoin concentrations decrease about 40%.</td>
</tr>
<tr>
<td align="left" valign="top">Propafenone</td>
<td align="left" colspan="2" valign="top">Decreases theophylline clearance and pharmacologic interaction.</td>
<td align="left" valign="top">40% increase. Beta-2 blocking effect may decrease efficacy of theophylline.</td>
</tr>
<tr>
<td align="left" valign="top">Propranolol</td>
<td align="left" colspan="2" valign="top">Similar to cimetidine and pharmacologic interaction.</td>
<td align="left" valign="top">100% increase. Beta-2 blocking effect may decrease efficacy of theophylline.</td>
</tr>
<tr>
<td align="left" valign="top">Rifampin</td>
<td align="left" colspan="2" valign="top">Increases theophylline clearance by increasing cytochrome P450 1A2 and 3A3 activity.</td>
<td align="left" valign="top">20-40% decrease</td>
</tr>
<tr>
<td align="left" valign="top">Sulfinpyrazone</td>
<td align="left" colspan="2" valign="top">Increases theophylline clearance by increasing demethylation and hydroxylation. Decreases renal clearance of theophylline.</td>
<td align="left" valign="top">20% decrease</td>
</tr>
<tr>
<td align="left" valign="top">Tacrine	</td>
<td align="left" colspan="2" valign="top">Similar to cimetidine, also increases renal clearance of theophylline.</td>
<td align="left" valign="top">90% increase</td>
</tr>
<tr>
<td align="left" valign="top">Thiabendazole</td>
<td align="left" colspan="2" valign="top">Decreases theophylline clearance.</td>
<td align="left" valign="top">190% increase</td>
</tr>
<tr>
<td align="left" valign="top">Ticlopidine</td>
<td align="left" colspan="2" valign="top">Decreases theophylline clearance.</td>
<td align="left" valign="top">60% increase</td>
</tr>
<tr>
<td align="left" valign="top">Troleandomycin</td>
<td align="left" colspan="2" valign="top">Similar to erythromycin.</td>
<td align="left" valign="top">33-100% increase depending on troleandomycin dose.</td>
</tr>
<tr class="Last">
<td align="left" valign="top">Verapamil</td>
<td align="left" colspan="2" valign="top">Similar to disulfiram.</td>
<td align="left" valign="top">20% increase</td>
</tr>
</tbody>
</table>
<table frame="void">
<caption><span>Table III. Drugs that have been documented not to interact with theophylline or drugs that produce no clinically significant interaction with theophylline.*</span></caption>
<tfoot><tr class="First Last"><td align="left" colspan="4" valign="top">*Refer to <a href="#Section_6.4">PRECAUTIONS, Drug Interactions</a> for information regarding table.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td align="left" valign="top">albuterol,Â  systemic and inhaled</td>
<td align="left" valign="top">felodipinefinasteride</td>
<td align="left" valign="top">nizatidinenorfloxacin</td>
</tr>
<tr>
<td align="left" valign="top">amoxicillin</td>
<td align="left" valign="top">hydrocortisone</td>
<td align="left" valign="top">ofloxacin</td>
</tr>
<tr>
<td align="left" valign="top">ampicillin,Â Â  with or without sulbactam</td>
<td align="left" valign="top">isofluraneÂ isoniazid</td>
<td align="left" valign="top">omeprazoleÂ prednisone, prednisolone</td>
</tr>
<tr>
<td align="left" valign="top">atenolol</td>
<td align="left" valign="top">isradipine</td>
<td align="left" valign="top">ranitidine</td>
</tr>
<tr>
<td align="left" valign="top">azithromycin</td>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">influenza</span> vaccine</td>
<td align="left" valign="top">rifabutin</td>
</tr>
<tr>
<td align="left" valign="top">caffeine,Â Â  dietary ingestion</td>
<td align="left" valign="top">ketoconazoÂ lelomefloxacin</td>
<td align="left" valign="top">roxithromycinÂ sorbitol</td>
</tr>
<tr>
<td align="left" valign="top">cefaclor</td>
<td align="left" valign="top">mebendazole</td>
<td align="left" valign="top">Â Â Â Â Â Â Â  (purgative doses do not </td>
</tr>
<tr>
<td align="left" valign="top">co-trimoxazoleÂ  (trimethoprim and sulfamethoxazole)</td>
<td align="left" valign="top">medroxyprogesteronemethylprednisolone</td>
<td align="left" valign="top">Â Â  inhibit theophyllineÂ Â  absorption)</td>
</tr>
<tr>
<td align="left" valign="top">diltiazem</td>
<td align="left" valign="top">metronidazole</td>
<td align="left" valign="top">sucralfate</td>
</tr>
<tr>
<td align="left" valign="top">dirithromycin</td>
<td align="left" valign="top">metoprolol</td>
<td align="left" valign="top">terbutaline, systemic</td>
</tr>
<tr>
<td align="left" valign="top">enflurane</td>
<td align="left" valign="top">nadolol</td>
<td align="left" valign="top">terfenadine</td>
</tr>
<tr>
<td align="left" valign="top">famotidine</td>
<td align="left" valign="top">nifedipine</td>
<td align="left" valign="top">tetracycline</td>
</tr>
<tr class="Last">
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top">tocainide</td>
</tr>
</tbody>
</table>
<p><span class="Bold">The Effect of Other Drugs on Theophylline Serum Concentration Measurements:</span></p>
<p>Most serum theophylline assays in clinical use are immunoassays which are specific for theophylline. Other xanthines such as caffeine, dyphylline, and pentoxifylline are not detected by these assays. Some drugs (e.g., cefazolin, cephalothin), however, may interfere with certain HPLC techniques. Caffeine and xanthine metabolites in neonates or patients with renal dysfunction may cause the reading from some dry reagent office methods to be higher than the actual serum theophylline concentration.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_6.6"></a><a name="section-6.6"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<p class="First">Long term carcinogenicity studies have been carried out in mice (oral doses 30-150 mg/kg) and rats (oral doses 5-75 mg/kg). Results are pending.</p>
<p>Theophylline has been studied in Ames <span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">salmonella</span>, <span class="Italics">in vivo</span> and <span class="Italics">in vitro</span> cytogenetics, micronucleus and Chinese hamster ovary test systems and has not been shown to be genotoxic.</p>
<p>In a 14 week continuous breeding study, theophylline, administered to mating pairs of B6C3F<span class="Sub">1</span> mice at oral doses of 120, 270 and 500 mg/kg (approximately 1.0-3.0 times the human dose on a mg/m<span class="Sup">2</span> basis) impaired fertility, as evidenced by decreases in the number of live pups per litter, decreases in the mean number of litters per fertile pair, and increases in the gestation period at the high dose as well as decreases in the proportion of pups born alive at the mid and high dose.</p>
<p>In 13 week toxicity studies, theophylline was administered to F344 rats and B6C3F<span class="Sub">1</span> mice at oral doses of 40-300 mg/kg (approximately 2.0 times the human dose on a mg/m<span class="Sup">2</span> basis). At the high dose, systemic toxicity was observed in both species including decreases in testicular weight.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_6.7"></a><a name="section-6.7"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Bold">CATEGORY C:</span> There are no adequate and well controlled studies in pregnant women. Additionally, there are no <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> studies in non-rodents (e.g., rabbits). Theophylline was not shown to be teratogenic in CD-1 mice at oral doses up to 400 mg/kg, approximately 2.0 times the human dose on a mg/m<span class="Sup">2</span> basis or in CD-1 rats at oral doses up to 260 mg/kg, approximately 3.0 times the recommended human dose on a mg/m2 basis. At a dose of 220 mg/kg, embryotoxicity was observed in rats in the absence of maternal toxicity.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_6.9"></a><a name="section-6.8"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Theophylline is excreted into breast milk and may cause <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span> or other signs of mild toxicity in nursing human infants. The concentration of theophylline in breast milk is about equivalent to the maternal serum concentration. An infant ingesting a liter of breast milk containing 10-20 mcg/mL of theophylline per day is likely to receive 10-20 mg of theophylline per day. Serious adverse effects in the infant are unlikely unless the mother has toxic serum theophylline concentrations.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_6.10"></a><a name="section-6.9"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Theophylline is safe and effective for the approved indications in pediatric patients (See <a href="#Section_3">INDICATIONS AND USAGE</a>). The maintenance dose of theophylline must be selected with caution in pediatric patients since the rate of theophylline clearance is highly variable across the age range of neonates to adolescents (see <a href="#table1">CLINICAL PHARMACOLOGY, Table I</a>,<a href="#Section_5">WARNINGS</a>, and <a href="#table5">DOSAGE AND ADMINISTRATION, Table V</a>). Due to the immaturity of theophylline metabolic pathways in infants under the age of one year, particular attention to dosage selection and frequent monitoring of serum theophylline concentrations are required when theophylline is prescribed to pediatric patients in this age group.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_6.11"></a><a name="section-6.10"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Elderly patients are at significantly greater risk of experiencing serious toxicity from theophylline than younger patients due to pharmacokinetic and pharmacodynamic changes associated with aging. Theophylline clearance is reduced in patients greater than 60 years of age, resulting in increased serum theophylline concentrations in response to a given theophylline dose. Protein binding may be decreased in the elderly resulting in a larger proportion of the total serum theophylline concentration in the pharmacologically active unbound form. Elderly patients also appear to be more sensitive to the toxic effects of theophylline after chronic overdosage than younger patients. For these reasons, the maximum daily dose of theophylline in patients greater than 60 years of age ordinarily should not exceed 400 mg/day unless the patient continues to be symptomatic and the peak steady state serum theophylline concentration is &lt;10 mcg/mL (see <a href="#Section_10">DOSAGE AND ADMINISTRATION</a>). Theophylline doses greater than 400 mg/d should be prescribed with caution in elderly patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions associated with theophylline are generally mild when peak serum theophylline concentrations are &lt;20 mcg/mL and mainly consist of transient caffeine-like adverse effects such as <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. When peak serum theophylline concentrations exceed 20 mcg/mL, however, theophylline produces a wide range of adverse reactions including <span class="product-label-link" type="condition" conceptid="27321" conceptname="Persistent vomiting">persistent vomiting</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, and intractable <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> which can be lethal (see <a href="#Section_9">OVERDOSAGE</a>). The transient caffeine-like adverse reactions occur in about 50% of patients when theophylline therapy is initiated at doses higher than recommended initial doses (e.g., &gt;300 mg/day in adults and &gt;12 mg/kg/day in children beyond &gt;1 year of age). During the initiation of theophylline therapy, caffeine-like adverse effects may transiently alter patient behavior, especially in school age children, but this response rarely persists. </p>
<p>Initiation of theophylline therapy at a low dose with subsequent slow titration to a predetermined age-related maximum dose will significantly reduce the frequency of these transient adverse effects (see <a href="#table5">DOSAGE AND ADMINISTRATION , Table V</a>). In a small percentage of patients (&lt;3% of children and &lt;10% of adults) the caffeine-like adverse effects persist during maintenance therapy, even at peak serum theophylline concentrations within the therapeutic range (i.e., 10-20 mcg/mL). Dosage reduction may alleviateÂ  the caffeine-like adverse effects in these patients, however, persistent adverse effects should result in a reevaluation of the need for continued theophylline therapy and the potential therapeutic benefit of alternative treatment.</p>
<p>Other adverse reactions that have been reported at serum theophylline concentrations &lt;20 mcg/mL include <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, fine skeletal muscle <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremors</span>, and transient <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span>. In patients with <span class="product-label-link" type="condition" conceptid="4306572" conceptname="Hypoxia">hypoxia</span> secondary to <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>, <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">multifocal atrial tachycardia</span> and flutter have been reported at serum theophylline concentrations â‰¥15 mcg/mL. There have been a few isolated reports of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> at serum theophylline concentrations &lt;20 mcg/mL in patients with an underlying neurological disease or in elderly patients. The occurrence of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in elderly patients with serum theophylline concentrations &lt;20 mcg/mL may be secondary to decreased protein binding resulting in a larger proportion of the total serum theophylline concentration in the pharmacologically active unbound form. The clinical characteristics of the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> reported in patients with serum theophylline concentrations &lt;20 mcg/mL have generally been milder than <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with excessive serum theophylline concentrations resulting from an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> (i.e., they have generally been transient, often stopped without anticonvulsant therapy, and did not result in neurological residua).</p>
<table frame="void">
<caption><span>Table IV. Manifestations of theophylline toxicity.*</span></caption>
<thead>
<tr class="First">
<th align="left" valign="top"></th>
<th align="center" colspan="4" valign="top">Percentage of patients reported with sign or symptom</th>
</tr>
<tr>
<td align="left" valign="top"></td>
<th align="center" colspan="2" valign="top"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Acute Overdose</span><br>(Large Single Ingestion)</th>
<th align="center" colspan="2" valign="top">Chronic Overdosage<br> (Multiple Excessive Doses)</th>
</tr>
<tr class="Last">
<th align="left" valign="top">
                    Sign/Symptom
                  </th>
<th align="center" valign="top">Study 1<br>(n=157)
                  </th>
<th align="center" valign="top">Study 2<br>(n=14)</th>
<th align="center" valign="top">Study 1<br>(n=92)</th>
<th align="center" valign="top">Study 2<br>(n=102)</th>
</tr>
</thead>
<tfoot>
<tr class="First"><td colspan="5">*These data are derived from two studies in patients with serum theophylline concentrations &gt;30 mcg/mL. In the first study (Study #1 - Shanon, Ann Intern Med 1993;119:1161-67), data were prospectively collected from 249 consecutive cases of theophylline toxicity referred to a regional poison center for consultation. In the second study (Study #2 - Sessler, Am J Med 1990;88:567-76), data were retrospectively collected from 116 cases with serum theophylline concentrations &gt;30 mcg/mL among 6000 blood samples obtained for measurement of serum theophylline concentrations in three emergency departments. Differences in the incidence of manifestations of theophylline toxicity between the two studies may reflect sample selection as a result of study design (e.g., in Study #1, 48% of the patients had acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxications</span> versus only 10% in Study #2) and different methods of reporting results.</td></tr>
<tr class="Last"><td colspan="5">**NR = Not reported in a comparable manner.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left" valign="top"><span class="Underline">Asymptomatic	</span></td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">6</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline">Gastrointestinal</span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center" valign="top">73</td>
<td align="center" valign="top">93</td>
<td align="center" valign="top">30</td>
<td align="center" valign="top">61</td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span></td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">21</td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">12</td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">14</td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">Hematemesis</span></td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">2</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline">Metabolic/Other</span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span></td>
<td align="center" valign="top">85</td>
<td align="center" valign="top">79</td>
<td align="center" valign="top">44</td>
<td align="center" valign="top">43</td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span></td>
<td align="center" valign="top">98</td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">18</td>
<td align="center" valign="top">NR**</td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â Acid/base disturbance</td>
<td align="center" valign="top">34</td>
<td align="center" valign="top">21</td>
<td align="center" valign="top">9</td>
<td align="center" valign="top">5</td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">Rhabdomyolysis</span></td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">7</td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline">Cardiovascular</span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">Sinus tachycardia</span></td>
<td align="center" valign="top">100</td>
<td align="center" valign="top">86</td>
<td align="center" valign="top">100</td>
<td align="center" valign="top">62</td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â Other supraventricular<br>Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardias</span></td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">21</td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">14</td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â Ventricular <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">premature beats</span></td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">21</td>
<td align="center" valign="top">10</td>
<td align="center" valign="top">19</td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span> or flutter</td>
<td align="center" valign="top">1</td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">12</td>
<td align="center" valign="top">NR**</td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4171269" conceptname="Atrial tachycardia">Multifocal atrial tachycardia</span></td>
<td align="center" valign="top">0</td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">2</td>
<td align="center" valign="top">NR**</td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular arrhythmias</span> with<br>Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4311860" conceptname="Hemodynamic instability">hemodynamic instability</span></td>
<td align="center" valign="top">7</td>
<td align="center" valign="top">14</td>
<td align="center" valign="top">40</td>
<td align="center" valign="top">0</td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>/<span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span></td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">21</td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">8</td>
</tr>
<tr>
<td align="left" valign="top"><span class="Underline">Neurologic</span></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
<td align="left" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">64</td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">21</td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremors</span></td>
<td align="center" valign="top">38</td>
<td align="center" valign="top">29</td>
<td align="center" valign="top">16</td>
<td align="center" valign="top">14</td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">Disorientation</span></td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">7</td>
<td align="center" valign="top">NR**</td>
<td align="center" valign="top">11</td>
</tr>
<tr>
<td align="left" valign="top">Â Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></td>
<td align="center" valign="top">5</td>
<td align="center" valign="top">14</td>
<td align="center" valign="top">14</td>
<td align="center" valign="top">5</td>
</tr>
<tr class="Last">
<td align="left" valign="top"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></span></td>
<td align="center" valign="top">3</td>
<td align="center" valign="top">21</td>
<td align="center" valign="top">10</td>
<td align="center" valign="top">4</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_9"></a><a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_9.1"></a><a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">The chronicity and pattern of theophylline overdosage significantly influences clinical manifestations of toxicity, management and outcome. There are two common presentations: (1) <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span>, i.e., ingestion of a single large excessive dose (&gt;10 mg/kg) as occurs in the context of an <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">attempted suicide</span> or isolated medication error, and (2) chronic overdosage, i.e., ingestion of repeated doses that are excessive for the patientâ€™s rate of theophylline clearance. The most common causes of chronic theophylline overdosage include patient or care giver error in dosing, clinician prescribing of an excessive dose or a normal dose in the presence of factors known to decrease the rate of theophylline clearance, and increasing the dose in response to an exacerbation of symptoms without first measuring the serum theophylline concentration to determine whether a dose increase is safe.</p>
<p>Severe toxicity from theophylline <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is a relatively rare event. In one health maintenance organization, the frequency of hospital admissions for chronic overdosage of theophylline was about 1 per 1000 person-years exposure. In another study, among 6000 blood samples obtained for measurement of serum theophylline concentration, for any reason, from patients treated in an emergency department, 7% were in the 20-30 mcg/mL range and 3% were &gt;30 mcg/mL. Approximately two-thirds of the patients with serum theophylline concentrations in the 20-30 mcg/mL range had one or more manifestations of toxicity while &gt;90% of patients with serum theophylline concentrations &gt;30mcg/mL were clinically intoxicated. Similarly, in other reports, serious toxicity from theophylline is seen principally at serum concentrations &gt;30 mcg/mL.</p>
<p>Several studies have described the clinical manifestations of theophylline <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> and attempted to determine the factors that predict life-threatening toxicity. In general, patients who experience an <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdose</span> are less likely to experience <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> than patients who have experienced a chronic overdosage, unless the peak serum theophylline concentration is &gt;100 mcg/mL. After a chronic overdosage, generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur at serum theophylline concentrations &gt;30 mcg/mL. The severity of toxicity after chronic overdosage is more strongly correlated with the patientâ€™s age than the peak serum theophylline concentration; patients &gt;60 years are at the greatest risk for severe toxicity and mortality after a chronic overdosage. Pre-existing or concurrent disease may also significantly increase the susceptibility of a patient to a particular toxic manifestation, e.g., patients with neurologic disorders have an increased risk of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and patients with cardiac disease have an increased risk of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> for a given serum theophylline concentration compared to patients without the underlying disease.</p>
<p>The frequency of various reported manifestations of theophylline <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> according to the mode of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> are listed in Table IV.</p>
<p>Other manifestations of theophylline toxicity include increases in serum calcium, creatine kinase, myoglobin and leukocyte count, decreases in serum phosphate and magnesium, <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">acute myocardial infarction</span>, and <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> in men with <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">obstructive uropathy</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span> associated with serum theophylline concentrations &gt;30 mcg/mL are often resistant to anticonvulsant therapy and may result in irreversible brain injury if not rapidly controlled. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> from theophylline toxicity is most often secondary to cardiorespiratory arrest and/or <span class="product-label-link" type="condition" conceptid="377845" conceptname="Anoxic encephalopathy">hypoxic encephalopathy</span> following prolonged generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or intractable <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> causing hemodynamic compromise.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_9.2"></a><a name="section-8.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> Management</h2>
<p class="First"><span class="Bold"><span class="Underline">General Recommendations for Patients with Symptoms of Theophylline <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> or Serum Theophylline Concentrations &gt;30 mcg/mL (Note: Serum theophylline concentrations may continue to increase after presentation of the patient for medical care.)</span></span></p>
<ol class="Arabic">
<li>While simultaneously instituting treatment, contact a regional poison center to obtain updated information and advice on individualizing the recommendations that follow.</li>
<li>Institute supportive care, including establishment of intravenous access, maintenance of the airway, and electrocardiographic monitoring.Â Â </li>
<li>
<span class="Underline">Treatment of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span></span> Because of the high morbidity and mortality associated with theophylline-induced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, treatment should be rapid and aggressive. Anticonvulsant therapy should be initiated with an intravenous benzodiazepine, e.g., diazepam, in increments of 0.1-0.2 mg/kg every 1-3 minutes until <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> are terminated. Repetitive <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> should be treated with a loading dose of phenobarbital (20 mg/kg infused over 30- 60 minutes). Case reports of theophylline <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> in humans and animal studies suggest that phenytoin is ineffective in terminating theophylline-induced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. The doses of benzodiazepines and phenobarbital required to terminate theophylline-induced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> are close to the doses that may cause severe <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> or <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>; the clinician should therefore be prepared to provide assisted ventilation. Elderly patients and patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span> may be more susceptible to the respiratory depressant effects of anticonvulsants. Barbiturate-induced <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> or administration of general anesthesia may be required to terminate repetitive <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>. General anesthesia should be used with caution in patients with theophylline <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> because fluorinated volatile anesthetics may sensitize the myocardium to endogenous catecholamines released by theophylline. Enflurane appears to less likely to be associated with this effect than halothane and may, therefore, be safer. Neuromuscular blocking agents alone should not be used to terminate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> since they abolish the musculoskeletal manifestations without terminating <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> activity in the brain.</li>
<li>
<span class="Underline">Anticipate Need for Anticonvulsants</span> In patients with theophylline <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> who are at high risk for theophylline induced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, e.g., patients with <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">acute overdoses</span> and serum theophylline concentrations &gt;100 mcg/mL chronic overdosage in patients &gt;60 years of age with serum theophylline concentrations &gt;30 mcg/mL, the need for anticonvulsant therapy should be anticipated. A benzodiazepine such as diazepam should be drawn into a syringe and kept at the patientâ€™s bedside and medical personnel qualified to treat <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> should be immediately available. In selected patients at high risk for theophylline-induced <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, consideration should be given to the administration of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> anticonvulsant therapy. Situations where <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> anticonvulsant therapy should be considered in high risk patients include anticipated delays in instituting methods for extracorporeal removal of theophylline (e.g., transfer of a high risk patient from one health care facility to another for extracorporeal removal) and clinical circumstances that significantly interfere with efforts to enhance theophylline clearance (e.g., a neonate where dialysis may not be technically feasible or a patient with <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> unresponsive to antiemetics who is unable to tolerate multiple-dose oral activated charcoal). In animal studies, <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> administration of phenobarbital, but not phenytoin, has been shown to delay the onset of theophylline induced generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and to increase the dose of theophylline required to induce <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (i.e., markedly increases the LD50). Although there are no controlled studies in humans, a loading dose of intravenous phenobarbital (20 mg/kg infused over 60 minutes) may delay or prevent life-threatening <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in high risk patients while efforts to enhance theophylline clearance are continued. Phenobarbital may cause <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, particularly in elderly patients and patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>.</li>
<li>
<span class="Underline">Treatment of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span></span> <span class="product-label-link" type="condition" conceptid="4007310" conceptname="Sinus tachycardia">Sinus tachycardia</span> and simple ventricular <span class="product-label-link" type="condition" conceptid="316429" conceptname="Premature beats">premature beats</span> are not harbingers of life-threatening <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, they do not require treatment in the absence of hemodynamic compromise, and they resolve with declining serum theophylline concentrations. Other <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, especially those associated with hemodynamic compromise, should be treated with antiarrhythmic therapy appropriate for the type of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>.</li>
<li>
<span class="Underline">Gastrointestinal decontamination</span> Oral activated charcoal (0.5 g/kg up to 20 g and repeat at least once 1-2 hours after the first dose) is extremely effective in blocking the absorption of theophylline throughout the gastrointestinal tract, even when administered several hours after ingestion. If the patient is <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, the charcoal should be administered through a nasogastric tube or after administration of an antiemetic. Phenothiazine antiemetics such as prochlorperazine or perphenazine should be avoided since they can lower the <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> threshold and frequently cause <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonic reactions</span>. A single dose of sorbitol may be used to promote stooling to facilitate removal of theophylline bound to charcoal from the gastrointestinal tract. Sorbitol, however, should be dosed with caution since it is a potent purgative which can cause profound fluid and electrolyte abnormalities, particularly after multiple doses. Commercially available fixed combinations of liquid charcoal and sorbitol should be avoided in young children and after the first dose in adolescents and adults since they do not allow for individualization of charcoal and sorbitol dosing. Ipecac syrup should be avoided in theophylline <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>. Although ipecac induces <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, it does not reduce the absorption of theophylline unless administered within 5 minutes of ingestion and even then is less effective than oral activated charcoal. Moreover, ipecac induced <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> may persist for several hours after a single dose and significantly decrease the retention and the effectiveness of oral activated charcoal.</li>
<li>
<span class="Underline">Serum Theophylline Concentration Monitoring</span> The serum theophylline concentration should be measured immediately upon presentation, 2-4 hours later, and then at sufficient intervals, e.g., every 4 hours, to guide treatment decisions and to assess the effectiveness of therapy. Serum theophylline concentrations may continue to increase after presentation of the patient for medical care as a result of continued absorption of theophylline from the gastrointestinal tract. Serial monitoring of serum theophylline serum concentrations should be continued until it is clear that the concentration is no longer rising and has returned to non-toxic levels.</li>
<li>
<span class="Underline">General Monitoring Procedures</span> Electrocardiographic monitoring should be initiated on presentation and continued until the serum theophylline level has returned to a non-toxic level. Serum electrolytes and glucose should be measured on presentation and at appropriate intervals indicated by clinical circumstances. Fluid and electrolyte abnormalities should be promptly corrected. <span class="Bold">Monitoring and treatment should be continued until the serum concentration decreases below 20 mcg/mL.</span>
</li>
<li>
<span class="Underline">Enhance clearance of theophylline</span> Multiple-dose oral activated charcoal (e.g., 0.5 mg/kg up to 20 g, every two hours) increases the clearance of theophylline at least twofold by adsorption of theophylline secreted into gastrointestinal fluids. Charcoal must be retained in, and pass through, the gastrointestinal tract to be effective; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> should therefore be controlled by administration of appropriate antiemetics. Alternatively, the charcoal can be administered continuously through a nasogastric tube in conjunction with appropriate antiemetics. A single dose of sorbitol may be administered with the activated charcoal to promote stooling to facilitate clearance of the adsorbed theophylline from the gastrointestinal tract. Sorbitol alone does not enhance clearance of theophylline and should be dosed with caution to prevent excessive stooling which can result in severe fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalances</span>. Commercially available fixed combinations of liquid charcoal and sorbitol should be avoided in young children and after the first dose in adolescents and adults since they do not allow for individualization of charcoal and sorbitol dosing. In patients with intractable <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, extracorporeal methods of theophylline removal should be instituted (see <a href="#Section_9.4">OVERDOSAGE, Extracorporeal Removal</a>).</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_9.3"></a><a name="section-8.3"></a><p></p>
<h2>Specific Recommendations</h2>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Acute Overdose</span></span></p>
<p>A. <span class="Underline">Serum Concentration &gt;20&lt;30 mcg/mL</span></p>
<ol class="Arabic">
<li>Administer a single dose of oral activated charcoal.</li>
<li>Monitor the patient and obtain a serum theophylline concentration in 2-4 hours to insure that the concentration is not increasing.</li>
</ol>
<p>B. <span class="Underline">Serum Concentration &gt;30&lt;100 mcg/mL</span></p>
<ol class="Arabic">
<li>Administer multiple dose oral activated charcoal and measures to control <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>.</li>
<li>Monitor the patient and obtain serial theophylline concentrations every 2-4 hours to gaugeÂ the effectiveness of therapy and to guide further treatment decisions.</li>
<li>Institute extracorporeal removal if <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> cannot be adequately controlled (see <a href="#Section_9.4">OVERDOSAGE, Extracorporeal Removal</a>).</li>
</ol>
<p>C. <span class="Underline">Serum Concentration &gt;100 mcg/mL</span></p>
<ol class="Arabic">
<li>Consider <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> anticonvulsant therapy.</li>
<li>Administer multiple-dose oral activated charcoal and measures to control <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>.</li>
<li>Consider extracorporeal removal, even if the patient has not experienced a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (see <a href="#Section_9.4">OVERDOSAGE, Extracorporeal Removal</a>).</li>
<li>Monitor the patient and obtain serial theophylline concentrations every 2-4 hours to gauge the effectiveness of therapy and to guide further treatment decisions.</li>
</ol>
<p><span class="Underline"><span class="Bold">Chronic Overdosage</span></span></p>
<p> Â 
                </p>
<p>A. <span class="Underline">Serum Concentration &gt;20&lt;30 mcg/mL (with manifestations of theophylline toxicity)</span></p>
<ol class="Arabic">
<li>Administer a single dose of oral activated charcoal.</li>
<li>Monitor the patient and obtain a serum theophylline concentration in 2-4 hours to insure that the concentration is not increasing.</li>
</ol>
<p>B. <span class="Underline">Serum Concentration &gt;30 mcg/mL in patients &lt;60 years of age</span></p>
<ol class="Arabic">
<li>Administer multiple-dose oral activated charcoal and measures to control <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>.</li>
<li>Monitor the patient and obtain serial theophylline concentrations every 2-4 hours to gauge the effectiveness of therapy and to guide further treatment decisions.</li>
<li>Institute extracorporeal removal if <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, or <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> cannot be adequately controlled (see <a href="#Section_9.4">OVERDOSAGE, Extracorporeal Removal</a>).</li>
</ol>
<p>C. <span class="Underline">Serum Concentration &gt;30 mcg/mL in patients â‰¥60 years of age.</span></p>
<ol class="Arabic">
<li>Consider <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> anticonvulsant therapy.</li>
<li>Administer multiple-dose oral activated charcoal and measures to control <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>.</li>
<li>Consider extracorporeal removal even if the patient has not experienced a <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (see <a href="#Section_9.4">OVERDOSAGE, Extracorporeal Removal</a>).</li>
<li>Monitor the patient and obtain serial theophylline concentrations every 2-4 hours to gauge the effectiveness of therapy and to guide further treatment decisions.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_9.4"></a><a name="section-8.4"></a><p></p>
<h2>Extracorporeal Removal</h2>
<p class="First">Increasing the rate of theophylline clearance by extracorporeal methods may rapidly decrease serum concentrations, but the risks of the procedure must be weighed against the potential benefit. Charcoal hemoperfusion is the most effective method of extracorporeal removal, increasing theophylline clearance up to six fold, but serious complications, including <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, platelet consumption and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> diatheses may occur. Hemodialysis is about as efficient as multiple-dose oral activated charcoal and has a lower risk of serious complications than charcoal hemoperfusion. Hemodialysis should be considered as an alternative when charcoal hemoperfusion is not feasible and multiple-dose oral charcoal is ineffective because of intractable <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>. Serum theophylline concentrations may rebound 5-10 mcg/mL after discontinuation of charcoal hemoperfusion or hemodialysis due to redistribution of theophylline from the tissue compartment. Peritoneal dialysis is ineffective for theophylline removal; exchange transfusions in neonates have been minimally effective.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_10.1"></a><a name="section-9.1"></a><p></p>
<h2>General Considerations</h2>
<p class="First">The steady-state peak serum theophylline concentration is a function of the dose, the dosing interval, and the rate of theophylline absorption and clearance in the individual patient. Because of marked individual differences in the rate of theophylline clearance, the dose required to achieve a peak serum theophylline concentration in the 10-20 mcg/mL range varies fourfold among otherwise similar patients in the absence of factors known to alter theophylline clearance (e.g., 400-1600 mg/day in adults &lt;60 years old and 10-36 mg/kg/day in children 1-9 years old). For a given population there is no single theophylline dose that will provide both safe and effective serum concentrations for all patients. Administration of the median theophylline dose required to achieve a therapeutic serum theophylline concentration in a given population may result in either sub-therapeutic or potentially toxic serum theophylline concentrations in individual patients. For example, at a dose of 900 mg/d in adults &lt;60 years or 22 mg/kg/d in children 1-9 years, the steady state peak serum theophylline concentration will be &lt;10 mcg/mL in about 30% of patients, 10-20 mcg/mL in about 50% and 20-30 mcg/mL in about 20% of patients. <span class="Bold"><span class="Underline">The dose of theophylline must be individualized on the basis of peak serum theophylline concentration measurements in order to achieve a dose that will provide maximum potential benefit with minimal risk to adverse effects.</span></span></p>
<p>Transient caffeine-like adverse effects and excessive serum concentrations in slow metabolizers can be avoided in most patients by starting with a sufficiently low dose and slowly increasing the dose, if judged to be clinically indicated, in small increments (See Table V). Dose increases should only be made if the previous dosage is well tolerated and at intervals of no less than 3 days to allow serum theophylline concentrations to reach the new steady state. Dosage adjustment should be guided by serum theophylline concentration measurement (see <a href="#Section_6.3">PRECAUTIONS, Laboratory Tests</a> and <a href="#table6">DOSAGE AND ADMINISTRATION, Table VI</a>). Health care providers should instruct patients and care givers to discontinue any dosage that causes adverse effects, to withhold the medication until these symptoms are gone and to then resume therapy at a lower, previously tolerated dosage (see <a href="#Section_5">WARNINGS</a>).</p>
<p>If the patientâ€™s symptoms are well controlled, there are no apparent adverse effects, and no intervening factors that might alter dosage requirements (see <a href="#Section_5">WARNINGS</a> and <a href="#Section_6">PRECAUTIONS</a>), serum theophylline concentrations should be monitored at 6 month intervals for rapidly growing children and at yearly intervals for all others. In acutely ill patients, serum theophylline concentrations should be monitored at frequent intervals, e.g., every 24 hours. </p>
<p>Theophylline distributes poorly into body fat, therefore, mg/kg dose should be calculated on the basis of ideal body weight.</p>
<p>Table V contains theophylline dosing titration schema recommended for patients in various age groups and clinical circumstances. Table VI contains recommendations for theophylline dosage adjustment based upon serum theophylline concentrations. <span class="Bold"><span class="Underline">Application of these general dosing recommendations to individual patients must take into account the unique clinical characteristics of each patient. In general, these recommendations should serve as the upper limit for dosage adjustments in order to decrease the risk of potentially serious adverse events associated with unexpected large increases in serum theophylline concentration.</span></span></p>
<p><span class="Bold">Table V. Dosing initiation and titration (as anhydrous theophylline).*</span></p>
<p><span class="Bold">
                    A. <span class="Underline">Infants &lt;1 year old.</span></span></p>
<ol class="Arabic">
<li>
<p class="First"><span class="Underline">Initial Dosage.</span></p>
<ol class="LittleAlpha">
<li>
<p class="First">Premature Neonates:</p>
<ol class="LittleRoman">
<li><p class="First">&lt; 24 days postnatal age; 1.0 mg/kg every 12 hr</p></li>
<li><p class="First">â‰¥Â  24 days postnatal age; 1.5 mg/kg every 12 hr</p></li>
</ol>
</li>
<li>
<p class="First">Full term infants and infants up to 52 weeks of age:</p>
<p><span class="Italics">Total daily dose (mg) = [(0.2 xÂ  age in weeks)+5.0] xÂ  (Kg body Wt).</span></p>
<ol class="LittleRoman">
<li><p class="First">up to age 26 weeks; divide dose into 3 equal amounts administered at 8 hour intervals.</p></li>
<li><p class="First">&gt;26 weeks of age; divide dose into 4 equal amounts administered at 6 hour intervals.</p></li>
</ol>
</li>
</ol>
</li>
<li><p class="First"><span class="Underline">
                        Final Dosage.<br></span>Adjusted to maintain a peak steady state serum theophylline concentration of 5-10 mcg/ml in neonates and 10-15 mcg/mL in older infants (see Table VI). Since the time required to reach steady-state is a function of theophylline half-life, up to 5 days may be required to achieve steady state in a premature neonate while only 2-3 days may be required in a 6 month old infant without other risk factors for impaired clearance in the absence of a loading dose. <span class="Bold">If a serum theophylline concentration is obtained before steady state is achieved, the maintenance dose should not be increased, even if the serum theophylline concentration is &lt;10 mcg/mL. </span></p></li>
</ol>
<a name="table5"></a><table frame="void" width="80%">
<caption><span>B. Children (1-15 years) and adults (16-60 years) without risk factors for impaired clearance.</span></caption>
<thead><tr class="First Last">
<td valign="top"><span class="Italics">Titration Step</span></td>
<td align="left" valign="top"><span class="Italics">Children &lt; 45 kg</span></td>
<td align="left" valign="top"><span class="Italics">Children &gt; 45 kg and adults</span></td>
</tr></thead>
<tbody>
<tr class="First">
<td valign="top">1. Starting Dosage</td>
<td align="left" valign="top">12-14 mg/kg/day up to<br> a maximum of 300 mg/day<br> divided Q4-6 hrs*</td>
<td align="left" valign="top">300 mg/day divided Q6-8 hrs*Â </td>
</tr>
<tr>
<td valign="top">2. After 3 days, if<br> tolerated, increase<br> dose to:
                      </td>
<td align="left" valign="top">16 mg/kg/day up to a<br> maximum of 400 mg/day<br> divided Q4-6 hrs*</td>
<td align="left" valign="top">400 mg/day divided Q6-8 hrs*</td>
</tr>
<tr class="Last">
<td valign="top">3. After 3 more days,<br><span class="Underline">if tolerated</span>, increase<br> dose to:
                      </td>
<td align="left" valign="top">20 mg/kg/day<br> up to a maximum<br> of 600 mg/day<br> divided Q4-6 hrs*</td>
<td align="left" valign="top">600 mg/day divided Q6-8 hrs*</td>
</tr>
</tbody>
</table>
<p><span class="Bold">C.</span><span class="Bold Underline"> Patients With Risk Factors For Impaired Clearance, The Elderly (&gt;60 Years), And Those In Whom It Is Not Feasible To Monitor Serum Theophylline Concentrations:</span></p>
<p>
                  In children 1-15 years of age, the final theophylline dose should not exceed 16 mg/kg/day up to a maximum of 400 mg/day in the presence of risk factors for reduced theophylline clearance (see <a href="#Section_5">WARNINGS</a>) or if it is not feasible to monitor serum theophylline concentrations.
                </p>
<p>
                  In adolescents â‰¥16 years and adults, including the elderly, the final theophylline dose should not exceed 400 mg/day in the presence of risk factors for reduced theophylline clearance (see <a href="#Section_5">WARNINGS</a>) or if it is not feasible to monitor serum theophylline concentrations.
                </p>
<p><span class="Bold">D.</span><span class="Bold Underline"> Loading Dose for Acute Bronchodilatation: </span></p>
<p>An inhaled beta-2 selective agonist, alone or in combination with a systemically administered corticosteroid, is the most effective treatment for acute exacerbations of reversible airways obstruction. Theophylline is a relatively weak bronchodilator, is less effective than an inhaled beta-2 selective agonist and provides no added benefit in the treatment of acute <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>. If an inhaled or parenteral beta agonist is not available, a loading dose of an oral immediate release theophylline can be used as a temporary measure. A single 5 mg/kg dose of theophylline, in a patient who has not received any theophylline in the previous 24 hours, will produce an average peak serum theophylline concentration of 10 mcg/mL (range 5-15 mcg/mL). If dosing with theophylline is to be continued beyond the loading dose, the guidelines in Sections A.1.b., B.3, or C., above, should be utilized and serum theophylline concentration monitored at 24 hour intervals to adjust final dosage.</p>
<p>*	Patients with more rapid metabolism, clinically identified by higher than average dose requirements, should receive a smaller dose more frequently to prevent breakthrough symptoms resulting from low trough concentrations before the next dose. A reliably absorbed slow-release formulation will decrease fluctuations and permit longer dosing intervals.</p>
<a name="table6"></a><table frame="void" width="80%">
<caption><span>Table VI. Dosage adjustment guided by serum theophylline concentration.</span></caption>
<col width="40%">
<col width="40%">
<thead><tr class="First Last">
<td class="Botrule" align="left" valign="top"><span class="Bold">Peak Serum Concentration</span></td>
<td class="Botrule" align="left" valign="top"><span class="Bold">Dosage Adjustment</span></td>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="2" valign="top">
                        Â¶
                        Dose reduction and/or serum theophylline concentration measurement is indicated whenever adverse effects are present, physiologic abnormalities that can reduce theophylline clearance occur (e.g., sustained <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>), or a drug that interacts with theophylline is added or discontinued (see <a href="#AE2C7DF2-9A10-4C21-8B2A-0D4CF808AC94">WARNINGS</a>).
                      </td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule" align="left" valign="top">&lt;9.9 mcg/mL</td>
<td class="Toprule" align="left" valign="top">If symptoms are not controlled and current dosage is tolerated, increase dose about 25%. Recheck serum concentration after three days for further dosage adjustment.</td>
</tr>
<tr>
<td align="left" valign="top">10 to 14.9 mcg/mL</td>
<td align="left" valign="top">If symptoms are controlled and current dosage is tolerated, maintain dose and recheck serum concentration at 6-12 month intervals.Â¶ If symptoms are not controlled and current dosage is tolerated consider adding additional medication(s) to treatment regimen.</td>
</tr>
<tr>
<td align="left" valign="top">15-19.9 mcg/mL</td>
<td align="left" valign="top">Consider 10% decrease in dose to provide greater margin of safety even if current dosage is tolerated.Â¶</td>
</tr>
<tr>
<td align="left" valign="top">20-24.9 mcg/mL</td>
<td align="left" valign="top">Decrease dose by 25% even if no adverse effects are present. Recheck serum concentration after 3 days to guide further dosage adjustment.</td>
</tr>
<tr>
<td align="left" valign="top">25-30 mcg/mL</td>
<td align="left" valign="top">Skip next dose and decrease subsequent doses at least 25% even if no adverse effects are present. Recheck serum concentration after 3 days to guide further dosage adjustment. If symptomatic, consider whether <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> treatment is indicated (see recommendations for chronic overdosage).</td>
</tr>
<tr class="Last">
<td align="left" valign="top">&gt;30 mcg/mL</td>
<td align="left" valign="top">Treat <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> as indicated (see recommendations for chronic overdosage). If theophylline is subsequently resumed, decrease dose by at least 50% and recheck serum concentration after 3 days to guide further dosage adjustment.</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">ELIXOPHYLLIN Elixir is a clear red solution with a mixed fruit flavor. Each tablespoonful (15 mL) contains 80 mg theophylline anhydrous.</p>
<p>ELIXOPHYLLIN Elixir is available in bottles of</p>
<p> 473 mL Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  NDC 49708-644-90</p>
<p><span class="Bold">RECOMMENDED STORAGE</span></p>
<p>Store at 25<span class="Sup">o</span>C (77<span class="Sup">o</span>F); excursions permitted to 15<span class="Sup">o</span> - 30<span class="Sup">o</span>C (59<span class="Sup">o</span> - 86<span class="Sup">o</span>F) [see USP Controlled Room Temperature].</p>
<p>Dispense in tight container.</p>
<p>Manufactured by:</p>
<p>SUN Pharmaceutical Industries, Inc.</p>
<p>705 East Mulberry Street</p>
<p>Bryan, Ohio 43506</p>
<p>Distributed By:</p>
<p>Caraco Pharmaceutical Laboratories, Ltd.</p>
<p>1150 Elijah McCoy Drive</p>
<p>Detroit, MI 48202</p>
<p>Iss.: 11/2012</p>
<p>7231T01</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_18"></a><a name="section-11"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC 49708-644-90</span></p>
<p><span class="Bold">ELIXOPHYLLIN<span class="Sup">Â® </span>ELIXIR </span></p>
<p><span class="Bold">(THEOPHYLLINE ANHYDROUS)</span></p>
<p><span class="Bold">80 mg / 15 mL</span></p>
<p><span class="Bold">Rx only</span></p>
<p><span class="Bold">16 OUNCES </span></p>
<p><span class="Bold">(473 mL)</span></p>
<p><span class="Bold">Distributed by:</span></p>
<p><span class="Bold">CARACO PHARMACEUTICAL LABORATORIES, LTD.</span></p>
<p><span class="Bold">Detroit, Michigan 48202</span></p>
<p><img alt="80 mg/15 ml" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=2676f761-4fe5-40a9-a07d-ed2542847883&amp;name=elixophyllin-elixir.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ELIXOPHYLLINÂ 		
					</strong><br><span class="contentTableReg">theophylline anhydrous liquid</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49708-644</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>THEOPHYLLINE ANHYDROUS</strong> (THEOPHYLLINE ANHYDROUS) </td>
<td class="formItem">THEOPHYLLINE ANHYDROUS</td>
<td class="formItem">80Â mg Â inÂ 15Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>GLYCERIN</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SACCHARIN SODIUM</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C RED NO. 40</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALCOHOL</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ANHYDROUS CITRIC ACID</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">RED (clear red) </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem">TUTTI FRUTTI</td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49708-644-90</td>
<td class="formItem">473 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA085186</td>
<td class="formItem">10/01/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Caraco Pharma, Inc.
							(831527945)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Caraco Pharmaceutical Laboratories Ltd.</td>
<td class="formItem"></td>
<td class="formItem">791055549</td>
<td class="formItem">Manufacture(49708-644), Pack(49708-644), Analysis(49708-644)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 3/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>bfd3f76e-094c-4148-a74b-f10efed03685</div>
<div>Set id: 2676f761-4fe5-40a9-a07d-ed2542847883</div>
<div>Version: 4</div>
<div>Effective Time: 20140312</div>
</div>
</div>Â <div class="DistributorName">Caraco Pharma, Inc.</div></p>
</body></html>
